Phase I Study of Chimeric Antigen Receptor Engineered T Cells targeting CD33 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Grant Award Details
Grant Type:
Grant Number:
CLIN2-15087
Investigator(s):
Disease Focus:
Award Value:
$11,983,547
Status:
Active
Grant Application Details
Application Title:
Phase I Study of Chimeric Antigen Receptor Engineered T Cells targeting CD33 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Public Abstract:
Therapeutic Candidate or Device
Immune T cells from a patient’s transplant donor engineered to express chimeric antigen receptors for targeted leukemia killing
Indication
Relapsed or refractory acute myeloid leukemia
Therapeutic Mechanism
Upon adoptive transfer, patient specific immune T cells that express chimeric antigen receptors will specifically recognize and directly kill leukemia cells expressing CD33.
Unmet Medical Need
This proposal seeks to address the unmet medical need for more effective therapy against acute myeloid leukemia by engineering de novo antileukemia activity using patient specific chimeric antigen receptor modified T cells.
Project Objective
Phase 1 trial completed
Major Proposed Activities
Immune T cells from a patient’s transplant donor engineered to express chimeric antigen receptors for targeted leukemia killing
Indication
Relapsed or refractory acute myeloid leukemia
Therapeutic Mechanism
Upon adoptive transfer, patient specific immune T cells that express chimeric antigen receptors will specifically recognize and directly kill leukemia cells expressing CD33.
Unmet Medical Need
This proposal seeks to address the unmet medical need for more effective therapy against acute myeloid leukemia by engineering de novo antileukemia activity using patient specific chimeric antigen receptor modified T cells.
Project Objective
Phase 1 trial completed
Major Proposed Activities
- Manufacture and clinically evaluate CAR T cells in a diverse population
- Evaluate the safety and preliminary evidence of efficacy
- Prepare for a phase 2 clinical trial
Statement of Benefit to California:
This proposal aims to benefit the citizens of California by developing a more effective therapy against acute myeloid leukemia. This project will produce economic benefits through creation and maintenance of skilled jobs, along with purchasing of supplies from in-state companies. This project will further establish California has a leader in biomedical research both nationally and internationally.